KB707

Phase 2Biologic

KKrystal Biotech, Inc.

KB707 is one of 24 biologic programs targeting Solid Tumor Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor MalignanciesRecruiting

Locally Advanced or Metastatic Solid TumorsRecruiting

Solid Tumor MalignanciesPhase 2

Recruiting

Locally Advanced or Metastatic Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

37 competitors in Locally Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

10 2

Stivarga

Bayer

Phase 2

1 3

Afinitor

Novartis

Phase 2

1 4

OPDUALAG

Bristol-Myers Squibb

Phase 2

1 5

Budigalimab

AbbVie

Phase 1

1 6

BL-M08D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 7

KB707

KKrystal Biotech, Inc.

Phase 2

1 8

SYHA1813

SShanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 2

1 9

BC3195

BBiocity Biopharmaceutics Co., Ltd.

Phase 2

1 10

ASKB589

AAskGene Pharma, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Locally Advanced or Metastatic Solid Tumors

NCT05970497

Q3 2028

Phase 1/2Recruiting

Solid Tumor Malignancies

NCT06228326

Clinical

Trials by Indication[1]

Solid Tumor Malignancies1 trial

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting·KKrystal Biotech, Inc.·Phase 1/2·NCT06228326·250 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting·KKrystal Biotech, Inc.·Phase 1/2·NCT05970497·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for KB707. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KB707 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KB707. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Krystal Biotech, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: KKrystal Biotech, Inc.

KB707

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Solid Tumor Malignancies1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News